AstraZeneca's imfinzi gets approval in Japan
AstraZeneca
11,770.00p
17:00 10/10/24
AstraZeneca's Imfinzi has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer (SCLC), in combination with etoposide plus a choice of platinum chemotherapy, the company said on Friday.
FTSE 100
8,237.73
17:09 10/10/24
FTSE 350
4,544.04
16:55 10/10/24
FTSE All-Share
4,501.37
16:50 10/10/24
Pharmaceuticals & Biotechnology
22,269.71
16:55 10/10/24
The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the Phase III CASPIAN trial, showing Imfinzi plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival versus chemotherapy alone, it added.
SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly, despite initial response to chemotherapy.